MGMT and glioblastoma: Although survival extension by 16% in mice-bearing TMZ resistant, MGMT unmethylated GBM after BTZ+TMZ compared with TMZ alone was modest, in a recurrent setting this might amount to extended survival for this hard to treat patient group.